VI
Vivaan24
Community Contributor
Member since 2026
Views3Total number of views
Followers0Total number of followers
Comments0Total number of comments
No bio added yet
No link added
CSL is forecasted to achieve a profit margin growth of 9% in the next five years
CSL Limited represents a high-quality global healthcare franchise operating across plasma-derived therapies, vaccines, and specialty pharmaceuticals. What makes CSL particularly compelling is its combination of defensive earnings characteristics and long-term structural growth exposure.Read more
3
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
VI
AU$132.9
8.8% overvalued intrinsic discount
Vivaan24's Fair Value
Revenue
4.95% p.a.
Profit Margin
9.06%
Future PE
35.25x
Price in 2031
AU$188.4